Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Roche will pay $200 million to license Dicerna Pharmaceuticals’ RNA interference (RNAi) drug candidate for hepatitis B virus (HBV). Dicerna could also earn up to $1.5 billion in future payments for the molecule, which is in a Phase I clinical trial. The program will complement Roche’s experimental small-molecule and antisense oligonucleotide HBV treatments. Other companies developing RNAi therapies for HBV include Johnson & Johnson and Vir Biotechnology.
This article has been sent to the following recipient: